Date: 2011-09-01
Type of information: Licensing agreement
Compound: PEV7 therapeutic vaccine
Company: Pevion Biotech (Switzerland) CSL (Australia)
Therapeutic area: Infectious diseases - Gynecology - Women's health
Type agreement: licensing
manufacturing
production
Action mechanism:
Disease: Recurrent Vulvovaginal Candidiasis
Details: Pevion Biotech has granted to CSL Limited a right of first refusal for the commercialization of its therapeutic Candida vaccine PEV7 in Australia and New Zealand. PEV7 already obtained excellent preliminary clinical results showing that the therapeutic vaccine is safe and immunogenic in healthy volunteers. CSL obtained a right of first refusal to an exclusive license for the commercialization of Pevion’s PEV7 therapeutic vaccine in Australia and New Zealand. Further terms of the agreement were not disclosed. In addition to the granting of the PEV7 option, the two companies have signed a long-term supply agreement, whereby CSL manufactures certain biological components that are being used by Pevion in the in vitro assembly process of its virosomes. Virosomes are a regulatory and market-approved vaccine technology that fulfills multiple carrier and adjuvant functions in one. They form the basis of all of Pevion’s proprietary and partnered pipeline products. Pevion has developed the second generation of virosomes that allow alternative product formulations, such as capsules. The ongoing PEV7 Phase I study is designed to assess the safety and immunogenicity of the therapeutic vaccine candidate in healthy volunteers. Half of the subjects will receive intramuscular injections, while the other half will receive capsules, administered intravaginally. In total, the study will enroll 48 healthy women of childbearing age.
Financial terms: Financial details were not disclosed.
Latest news:
